Palatin Technologies Inc. (PTN)
Symbol Info
Listed Symbol PTN
Name Palatin Technologies Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-06-30
Latest Fiscal Revenue $67,134,758
Latest Fiscal EPS $0.12
Price Info
21 Day Moving Average $0.9148
21 Day EMA $0.927700
50 Day Moving Average $1.0466
50 Day EMA $1.014070
200 Day EMA $1.028300
200 Day Moving Average 0.978810
52 Week High $1.78
52 Week Low $0.59
52 Week Change $-4.021000
Alpha 0.012638
Beta 1.6702
Standard Deviation 0.225365
R2 0.066120
Periods 60
Share Information
10 Day Average Volume 1,524,952
20 Day Average Volume 1,428,764
30 Day Average Volume 1,686,917
50 Day Average Volume 3,861,571
Outstanding Shares 215,556,222
Float Shares 200,249,993
Percent Float 92.90%
Short Interest 23,252,972
Short Percent Float 10.80%
Short Interest Ratio 11.28
Short Date 2019-07-31
Holders
Institutions 141
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 2,765,339
Institute Holdings Percent 29.800000
Institute Sold Previous 3 Months 5,183,861
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 15,306,229
Price Change
7 Day Price Change $0.0009000
7 Day Percent Change 0.10%
21 Day Price Change $-0.0024
21 Day Percent Change -0.26%
30 Day Price Change $-0.0991
30 Day Percent Change -9.62%
Month To Date Price Change $0.0214
Month To Date Percent 2.35%
90 Day Price Change $-0.7091
90 Day Percent Change -43.24%
Quarter To Date $-0.2291
Quarter To Date Percent -19.75%
180 Day Price Change $0.141100
180 Day Percent Change 17.87%
200 Day Price Change $0.257400
200 Day Percent Change 38.22%
Year To Date $0.222500
Year To Date Percent 31.41%
Profile
Description Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
Details
Issue Type CS
Market Cap $200,661,287
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 215,556,222
CEO Carl Spana
Employees 19
Last Audit UQ
Classification
CIK 0000911216
Industry Medical Diagnostics & Research
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 4B Cedar Brook Drive
Cedar Brook Corporate Center
Cranbury, NJ 8512
Website https://www.palatin.com
Facisimile +1 609 495-2202
Telephone +1 609 495-2200
Email investors@palatin.com
Key Ratios
Profitability
EBIT Margin -18
EBITDA Margin -17.7
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $34,505
Revenue Per Share $0.0002
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $170,687,804
Price To Sales 5,815.426300
Price To Free Cash -12.7
PE High Last 5 Years -
Price To Book 11.8
Price To Cash Flow 109.4
PE Low Last 5 Years -
Price To Tangible Book 11.8
Financial Strength
Total Debt To Equity 0.1
Int Coverage -5.7
Current Ratio 4.2
Leverage Ratio 1.3
Quick Ratio 4.0
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -19.28
Return On Equity -35.32
Return On Capital -23.37
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
PTN
Palatin Te..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.